XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Note 14 - Litigation Settlement (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 06, 2023
Jun. 10, 2022
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2022
Mar. 31, 2022
Loss Contingency, Estimate of Possible Loss       $ 200     $ 200      
Litigation Settlement, Expense     $ 0 (544)   $ 0 (233)      
Equity Securities, FV-NI, Unrealized Gain (Loss)     $ 1,208 0   $ (373) 0      
Harvard Apparatus Regenerative Technology, Inc. (“HART”) [Member]                    
Investment Owned, Balance, Shares (in shares)     706,626     706,626        
Investment Owned, Fair Value     $ 3,800     $ 3,800        
Equity Securities, FV-NI, Unrealized Gain (Loss)     $ 1,200     $ (400)        
Biostage [Member] | Private Placement [Member]                    
Conversion of Stock, Amount Issued $ 6,000                  
Shares Issued, Price Per Share (in dollars per share) $ 6                  
Series E Preferred Stock in Biostage [Member]                    
Equity Securities without Readily Determinable Fair Value, Amount         $ 3,900          
Preferred Stock, Book Value, Inclusive of Accrued Dividends                 $ 4,000  
Convertible Preferred Stock [Member] | Biostage [Member]                    
Preferred Stock, Convertible, Conversion Price (in dollars per share) $ 6                  
Case in Suffolk Superior Court [Member]                    
Loss Contingency, Estimate of Possible Loss                   $ 5,200
Litigation Settlement, Expense         $ (4,900)     $ 300    
Case in Suffolk Superior Court [Member] | Convertible Preferred Stock [Member]                    
Stock Issued During Period, Shares, Issued For Settlement (in shares)   4,000                
Stock Issued During Period, Value, Issued for Settlement   $ 4,000                
Estimated Litigation Liability       $ 500     $ 500